55 news items
Page 2 of 3
vaexq6rnje92rvxnz1d7jwzzh14fnqrdg5t lbqwgrrfx9t3s3elcf2d
QDEL
5 Jun 24
tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (2) excess inventories
hk1xjs9mph2rb0713fimygu4ail 2swskho5kaoz86mtkn4bu0gz4kz59
QDEL
5 Jun 24
, and prospects: (1) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers
1w67y4b6nh067w8t3hapq8v8spk8x1ahhoc64m
QDEL
5 Jun 24
tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) that excess inventories
pvke 1t6ex5xq33b17g8fkljccdgc
QDEL
24 Apr 24
kits to customers than they could sell to consumers and healthcare providers. The Company suffered from excess inventories throughout the supply
ldf 4y8e8gv
OCGN
QDEL
SHCR
23 Apr 24
, the Company has generated a significant portion of its revenue through the sale of high-margin COVID-19 tests to government customers, healthcare
79nm0v8q ofuwom4
QDEL
22 Apr 24
customers than they could resell to healthcare providers and end customers; (2) excess inventories of COVID-19 tests existed throughout the supply chain
g0r8jmf4ojm69qentv5of5
QDEL
22 Apr 24
to healthcare providers and end customers; (2) that excess inventories of COVID-19 tests existed throughout the supply chain; (3) that, as a result
814mcv5gydqyav8mwcwgjt0he8hv0zc6krmwqmm150zs3r
QDEL
22 Apr 24
and/or concealed that: (a) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare
ts7dnjbphxr7by l8vex
QDEL
22 Apr 24
tests to government customers, healthcare providers (through its authorized distributors), and large retail pharmacy chains. QuidelOrtho manufactures
tpm5rj
QDEL
22 Apr 24
to investors that: (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare
wbcol199woctw3xh3iqeewf1fyc1qntvb
OCGN
QDEL
19 Apr 24
tests to government customers, healthcare providers (through its authorized distributors), and large retail pharmacy chains. QuidelOrtho manufactures
8akc3i
QDEL
19 Apr 24
to healthcare providers and end customers; (2) excess inventories of COVID-19 tests existed throughout the supply chain; (3) as a result, QuidelOrtho's
i2b4pqdtg8lwrafzkbcdvz1n0608i jpvz1vim3v8emwp1bgdm
QDEL
19 Apr 24
chain customers than they could resell to healthcare providers and end customers; (2) that excess inventories of COVID-19 tests existed throughout
48mpgud
QDEL
19 Apr 24
and pharmacy chain customers than they could resell to healthcare providers and end customers
emb99f9vhzw3ev6z7k3f3xhrm6fa
QDEL
19 Apr 24
resell to healthcare providers and end customers; (b) that excess inventories of COVID-19 tests existed throughout the supply chain; (c
i4no tz9vjbw4t
QDEL
18 Apr 24
to healthcare providers and end customers; (2) excess inventories of COVID-19 tests existed throughout the supply chain; (3) as a result
mta483jspyp4p45e911lr8yepn62783z8jdn6to1u47d5leyqd7tecic66d
QDEL
18 Apr 24
to healthcare providers and end customers; (2) that excess inventories of COVID-19 tests existed throughout the supply chain; (3) that, as a result
0sg3vwqotuku15px0p
QDEL
18 Apr 24
to healthcare providers and end customers; (b) that excess inventories of COVID-19 tests existed throughout the supply chain; (c) that, as a result
ay9myfkfizhcgyagcmqzk8htb 1de11jpof2gbsty7g8fiosm76puubz
QDEL
17 Apr 24
) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers
3ex 0r6vr
QDEL
17 Apr 24
to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (2) excess inventories of COVID-19